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Absrract. Hemodynamic studies have been performed 
in 15 male patients with mild to moderately severe 
essential hypertension. Studies were made after four 
weeks of placebo treatment and again after acute i.v. 
administration of propranolol (0.22 mg/kg) and after 
four weeks of oral propranolol therapy (160-320 mg 
daily). After acute /3-adrenergic blockade a significant 
reduction of cardiac index (Qi) occurred, while total 
peripheral resistance (TPR) increased significantly, re- 
sulting in unaltered BP. After four weeks of oral pro- 
pranolol the Qi remained significantly reduced, but TPR 
was readjusted towards the initial level, resulting in a 
reduction of BP in most patients. Major reductions of 
stimulated plasma renin activity were seen, but these 
were not correlated to the changes of BP, Qi or TPR. 
Studies of the baroreceptor reflex by means of i.v. 
administration of angiotensin suggested a change to- 
wards increased sensitivity, although this change did not 
achieve statistical significance. 
Antihypertensive effect of propranolol has been 
reported in several studies (6, 8, 14, 15, 20, 23). 
As most forms of established hypertension are 
characterized by increased total peripheral vascu- 
lar resistance (TPR) and normal cardiac output 
(Q) (5 ,  11, 171, the  antihypertensive properties of 
propranolol have been hard t o  explain in view of 
its predominantly cardiac effects. Several sugges- 
tions have been offered as tentative explanations, 
e.g. resetting of baroreceptors (19, central nerv- 
ous effects (61, adaptation of vascular resistance 
in response to  chronic reduction of Q (20) and 
local anesthetic effects on vasoconstrictor fibers 
(4). Lately, propranolol-induced reduction of plas- 
ma renin activity (PRA) in hypertensive patients 
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has been demonstrated (2, 9), which may be of 
importance in the hypotensive mechanism, espe- 
cially in conditions with high plasma renin. As the 
effects of acute and chronic administration of 
propranolol are  different, particularly in regard t o  
the effect on  BP (16, 20, 21), h r t h e r  confusion has 
resulted. 
For this reason the present study was designed 
with the intention of studying the antihypertensive 
effect of propranolol, particularly the hemo- 
dynamic alterations resulting from acute and 
chronic /.?-adrenergic blockade. We were interested 
t o  see whether TPR would readjust in the pres- 
ence of continuously reduced Q. In addition, 
special interest was directed t o  the study of baro- 
receptor sensitivity and whether a change would 
take place. Finally, PRA was studied with the 
intention of exploring connections between 
changes of renin and changes of peripheral vascu- 
lar resistance. 
MATERIAL AND METHODS 
Fifteen male patients with mild to moderate essential 
hypertension were studied. Their average age was 44 
years (range 26-66). The average known duration of 
hypertension was 6.5 years (range &17). Before entering 
the study all patients but two were receiving antihyper- 
tensive therapy, usually consisting of a-methyldopa 
and/or diuretics. 
Secondary causes of hypertension were excluded in 
all patients by a thorough clinical examination, rapid 
sequence i.v. pyelograms and laboratory studies (serum 
electrolytes, PRA and urinary excretion of aldosterone, 
epinephrine and norepinephrine). In addition ECG, 
chest X-ray, urine microscopy, serum creatinine, serum 
lipids and liver function were checked repeatedly during 
the study. 
All patients were told of the investigational nature of 
the study and gave their informed consent to participa- 
tion in it. 
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Plan of study 
After stopping all previous therapy, the patients were 
given placebo treatment in a single blind fashion on an 
outpatient basis. Placebo treatment continued for four 
weeks, after which the patients were hospitalized for 
baseline studies, including the first hemodynamic study. 
They were discharged after four days and were put on 
oral propranolol, 40 mg four times daily, as the sole 
antihypertensive treatment. After two weeks this dosage 
was increased to 80 mg four times daily unless a dias- 
tolic BP reduction of 15 mmHg or more was observed. 
Treatment with propranolol was continued for another 
two-week period. The average daily propranolol dosage 
during weeks 3 and 4 was 250 mg. After four weeks of 
oral propranolol treatment a repeated hemodynamic 
study was performed. 
Hemodynamic methods 
The hemodynamic studies were performed in the 
morning with the patients fasting. 
Systemic arterial pressure was measured in the 
brachial artery by a Statham strain gauge receptor 
(P  23 G). Mean arterial pressure (MAP) was calculated 
as the diastolic BP+ 1/3 of the pulse pressure. 
Q was determined by the indicator dilution technique 
(12)  using a Gilford densitometer and lndocyanine green 
(Cardio-Green). 
Respiratory movements were monitored continuously 
by means of a bellows attached around the chest and 
connected to  a strain gauge by a rubber tube. The 
standard leads of the ECG were connected and lead I 
was recorded continuously on  a Gilson polygraph to- 
gether with intraarterial BP, respiration and dye curves. 
Stroke volume (SV) was calculated by dividing Q by 
heart rate (HR). TPR was obtained by dividing MAP 
by Q and was expressed in arbitrary units (U). Q, TPR 
and SV were corrected for body surface area and the 
corresponding indices Qi, TPRi and SVi were derived. 
PRA was measured with a radioimmunoassay tech- 
nique (7) in the initial untreated state during tilt (stim- 
ulated), and again in the tilted position after acute and 
prolonged 8-adrenergic blockade. 
Hemodynamic study I 
The first resting Q was determined 15 min after all 
catheters were placed. The patients were then tilted to 
a 45" head-up position for 10 min and Q and PRA were 
determined. Approximately 10 min after resumption and 
under resting conditions the baroreceptor reflex was 
assessed. This was done by rapid i.v. administration of 
angiotensin (Hypertensin Qiba), usually 1.5 pg, while 
recording changes in BP and HR. Systolic BP was 
plotted against the corresponding R-R interval in the 
ECG, using the technique of Bristow et al. (1). Plotting 
was continued until the pressure peak occurred. No 
data during inspiration were used. Usually 15-30 points 
could be plotted in this way for each patient. The points 
were then analysed with a standard correlation test 
and only if a statistically significant correlation resulted 
@<0.05) was the BP/R-R slope used for further com- 
parisons. 
Propranolol was then administered intravenously, 
0.05 mg/kg b.wt. over 2 min. Q was determined 8 min 
after the completion of the injection. An additional 
amount of propranolol, 0.05 mg/kg, was then given 
and Q measurements were repeated after an identical 
interval. Finally, a thud injection of 0.12 mg pro- 
pranolol/kg was given, bringing the total dosage to 
0.22 mg/kg. Hemodynamic determinations were then 
repeated. The 10-min 45" head-up tilt was then 
repeated, at the end of which hemodynamics were de- 
termined. 
Hemodynamic study I1 
The second hemodynamic study was done at the same 
time of day and under identical conditions as the first 
study, but following four weeks of oral propranolol 
treatment. The same studies were repeated with the ex- 
ception that i.v. propranolol was not given and only one 
10-min period of tilt with Q and PRA measurements was 
performed. 
Statistically significant BP/R-K slopes were obtained 
at both the first and second hemodynamic study in 7 
patients. Only data from these 7 patients were used 
for comparisons (paired t-test). 
Assessment of padrenergic blockade 
The degree of P-adrenergic blockade was tested three 
times during the study by continuous i.v. infusion of a 
P-adrenergic stimulant-isoproterenol-while monitoring 
HR on the ECG. On each occasion HR was determined 
before the start of the infusion. lsoproterenol was then 
given in a constant i.v. infusion of 3 pg/ml at the rate 
of 1 ml/min for 3 min. The response to P-adrenergic 
stimulation was taken as the difference between the 
final HR and the HR before the start of the infusion. 
The first assessment of response to isoproterenol was 
made after four weeks of oral placebo treatment before 
any propranolol had been given. The second determina- 
tion was made after i.v. administration of 0.22 mg pro- 
pranolol/kg, and the final assessment after four weeks 
of oral propranolol therapy and approximately 2 hours 
after the last dose. 
Plasma propranolol determinations 
Plasma propranolol concentration was determined by 
fluorimetric technique (18)  by Ayerst Laboratories, 
Montreal, Canada. Blood samples were drawn 20 min 
after the completion of the i.v. injection of propranolol 
and again, following four weeks of oral treatment, 
approximately 90 min after the last dose. The plasma 
was separated by centrifugation and chilled to  4°C be- 
fore being sent in an isolated tube for analysis. 
Statistical methods 
Student's t-test, the t-test for paired observations and 
correlation coefficients were calculated using the Midas 
(Constat) computer program of the Statistical Research 
Laboratory at the University of Michigan. 
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Fig. l a  and b. Effect of 
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RESULTS 
Effect of intravenous propranolol 
As illustrated in Fig. l a ,  even 0.05 mg/kg of i.v. 
propranolol caused a marked drop of Qi from 2.76 
to 2.29 l/min.m2 (P<O.Ol) .  TPRi increased from 
41.3 to 48.5 U/mZ @<0.05), thereby minimizing 
the effect on MAP which remained virtually un- 
changed (108.3 vs. 107.2 mmHg,p>0.25). 
Further administration of propranolol, to a total 
dosage of 0.10 and 0.22 mg/kg, respectively, 
caused further non-significant reductions of Qi 
Table I. Hemodynamic changes at rest 
and increments of TPRi, while MAP remained un- 
changed (Fig. 1 a) .  The overall hemodynamic ef- 
fects are given in Table I. As illustrated in Fig. 
16, the reduction of Qi was mainly the effect of 
decreased HR, while SVi did not change signifi- 
cantly. 
Effect of four weeks of oral propranolol therapy 
The effect of four weeks of oral propranolol ther- 
apy was similar to the acute effects of i.v. pro- 
pranolol in that Qi remained at a significantly 
lower level than initially, albeit the reduction was 
Ropranolol 
Placebo I.v." Difference p <  OrallSp Differen& p< 
Qi (l/min.m2) 2.76 2.18 0.58 0.001 2.35 0.41 0.01 
MAP (mmHg) 108.3 109.9 1,7 n.s. 102.1 6.2 0.05 
TPRi (U/mZ) 41.3 52.3 11.0 0.005 43.9 2.6 n.s. 
HR (beatslmin) 76.0 67.1 8.9 o.ooo1 59.6 16.4 o.ooo1 
SVi (ml/m') 37.3 33.0 4.3 n.s. 40.2 2.9 n.s. 
0.22 mg/kg. For 4 weeks, 160-320 mg/day. Compared to measurement after placebo. 
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Fig. 2a  and h.  Effects of acute i.v. and chronic oral 
administration of propranolol (mean kS.E.M.).  Statis- 
tics as in Fig. t .  
not as pronounced (Table I ,  Fig. 2a). The reduc- 
tion of Qi was mainly an effect of reduced HR, 
whereas SVi did not change significantly (Fig. 2b). 
However, in contrast to the effect of acute p- 
adrenergic blockade there now was a reduction of 
MAP (Fig. 2 a ) .  TPRi was correspondingly less 
elevated than after acute propranolol and as a 
matter of fact was not significantly higher than in 
the untreated state. 
Analysis of the hemodynamic changes in inidvid- 
ual patients revealed that, while 12 patients 
showed reduced MAP after four weeks of pro- 
pranolol therapy, 3 showed no decrease or even 
an increased MAP. For this reason the 12 "re- 
sponders" were compared to the 3 "non- 
responders". 
Already after acute i.v. propranolol there was a 
significant difference in MAP between the two 
groups (MAP 105.9 vs. 121.4 mmHg, p<O.OS) 
(Fig. 3). As expected, this difference was even 
more pronounced after four weeks of oral pro- 
pranolol (MAP 97.1 vs. 122.2 mmHg, p<O.OOl). 
There were no significant differences between 
responders and non-responders regarding Qi, but 
Acto med. scand. 1% 
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after four weeks of oral propranolol responders 
had significantly lower TPRi (42.3 vs. 50.2 U; 
p<0.05)  (Fig. 3). Differences in HR and SVi were 
insignificant both after acute and chronic p- 
adrenergic blockade. 
Effects of tilt 
The hemodynamic effects of tilt in the untreated 
state, after acute i.v. propranolol and after 4 
weeks of oral therapy, are presented in Table 11. 
Propranolol blocked the HR response to tilt both 
after acute and chronic administration. The well 
known reduction of Q during tilt was observed 
also after acute, and to a lesser extent after 
chronic, p-adrenergic blockade. Finally, the 
chronic p-adrenergic blockade did not interfere 
with the homeostasis of BP during tilt. Significant 
increases of MAP were seen in this situation both 
after placebo and after 4 weeks of oral pro- 
pranolol. On the other hand a non-significant re- 
duction of MAP occurred after acute i.v. pro- 
pranolol. 
Effect on plasma renin activity 
PRA after tilt in the untreated state, after acute 
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Fig. 3. Effect of acute i.v. and chronic oral adminstra- 
tion of propranolol (mean fS.E.M.). Statistical com- 
parison is between responders (-) and non-responders 
(- - -) (Student's t-test). Probabilities as in Fig. 1. 
Table 11. Hernodynamic changes during tilt 
i.v. propranolol and after 4 weeks of oral therapy 
are presented in Table 111. The effect on PRA 
of chronic propranolol therapy was striking, 
causing a reduction of stimulated (tilted) PRA by 
85% (from 249 to 39 ng/100 ml/h, p<0.005). 
However, the reduction of PRA was not signifi- 
cantly correlated to the change of MAP, TPRi or 
Qi either in the recumbent or tilted position (cor- 
relation coefficients 0.077-0.104, p<0.25). Nei- 
ther was the change of PRA, expressed in percent, 
significantly correlated to the percentage change of 
MAP, TPRi or Qi either recumbent or tilted (cor- 
relation coefficients 0.000-0.387, p>O. 10). There 
was no difference between responders and non- 
responders in the reduction of PRA, the three non- 
responders showing reductions of 81, 90 and 96%, 
respectively, as compared to 85% for the entire 
group. 
Effect on baroreceptor reflex 
Only in 7 patients was a statistically significant 
correlation between systolic BP and R-R interval 
(BP/R-R slope) obtained after angiotensin injection 
both in the untreated state and after four weeks of 
oral propranolol. The average BP/R-R slope in 
the untreated state was 4.84 and after oral pro- 
pranolol 7.64. The difference, 2.80f1.06, did not 
quite achieve statistical significance @ = O .  115) 
(paired t-test). 
Effect of isoproterenol 
As described before, infusion of isoproterenol was 
used to assess the degree of /3-adrenergic blockade 
in all patients. In the initial untreated state the 
HR increased by 39.4 beatslmin (p<O.OOOI) in 
response to the i.v. infusion of 3 pglmin. There 
was no difference between responders (39.8) and 
non-responders (38.0) in this respect. After acute 
Placebo (n = 15)  I . v .  propranolol" (n= 12) Oral propranololb (n = 12) 
Differ- 
Rest Tilt ence p <  
Differ- 
Rest Tilt ence p <  
Differ- 
Rest Tilt ence p< 
Qi ( I/min.mz) 2.76 2.19 0.57 0.005 
MAP (mmHg) 108.3 119.6 11.3 0.0005 
TPRi (U/m2) 41.3 56.5 15.2 O.ooO1 
HR (beatslmin) 76.0 84.9 8.9 0.005 
SVi (ml/mz) 37.3 26.4 10.9 O.ooO1 
2.19 1.60 0.59 0.0005 
106.4 98.3 8.1 n.s. 
50.4 63.8 13.4 0.005 
69.5 69.8 0.3 ns. 
32.0 22.9 9.1 0.0001 
2.44 2.04 0.40 0.005 
103.4 110.3 6.9 0.005 
42.6 54.6 10.0 0.0005 
57.7 60.6 2.9 0.01 
42.7 34.4 8.3 0.0005 
~~ ~ 
a 0.22 mgjkg. For 4 weeks, 160-320 mg/d. (average 250 mg). 
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Table I l l .  PRA hefbrr und ufter pudrenergic 
blockude 
PRA (ng1100 ml/h) tilt 
I . v .  propranolol Oral propranolol 
Placebo (0.22 mg/kg) (160-320 mg/d.) 
248.7f69.8 204.7k70. I 39.0f 10.1 -p<o.o1 - 
t p<O.005 - 
i.v. administration of propranolol and repeated iso- 
proterenol infusion at the rate of 3 pglmin the 
HR did not increase significantly (1  .O beatdmin). 
Finally, following four weeks of oral propranolol 
the response to isoproterenol infusion was 5.3 
beats/min (the increase in responders being 6.1 
and in non-responders 2.0 beatshin),  indicating 
that all patients had a significant degree of p- 
adrenergic blockade. 
Plasma propranolol determinations 
Average plasma propranolol concentration after 
acute i.v. administration of 0.22 mg propranolol/ 
kg was 100.5k6.0 nglml and individual variations 
were small. Following four weeks of oral pro- 
pranolol treatment, at either 160 or 320 mg daily, 
the average plasma propranolol concentration was 
123.1 f46.1 nglml. More than ten-fold varia- 
tions between individual patients were observed. 
Correlations between the various hemodynamic 
and PRA changes and plasma propranolol con- 
centrations were not statistically significant either 
after acute i.v. or after prolonged oral administra- 
tion of propranolol. Nor was the response to iso- 
proterenol infusion significantly correlated to plas- 
ma propranolol concentration. 
DISCUSSION 
The effect of propranolol was studied in IS men 
with mild to moderately severe essential hyper- 
tension. In agreement with previously published 
results (6, 8, 14, IS, 20, 23) a BP reduction was 
seen in most cases following oral treatment. 
Hemodynamically it was obvious that the i.v. 
administration of even 0.05 mg propranolol/kg 
caused a significant reduction of HR and Q, while 
the decrease of SVi did not achieve statistical 
significance (Figs. I and 2). Doubling and quad- 
rupling the dose further decreased HR and Q. 
but the importance of these increments of dosage 
was minor. 
Just as important was the finding that BP was 
not affected by this acute decrease of Q. Con- 
sequently. the calculated TPR had increased to a 
degree corresponding to the decrement of Q. 
Obviously this is the effect which from a theoreti- 
cal point of view should be expected from a p- 
adre nergic bloc king agent . 
After four weeks of oral administration of pro- 
pranolol the Q and HR were still decreased. In 
contrast to the acute situation, however, the 
majority of patients now showed reduced BP with 
an accompanying reduction of TPR. This finding 
is in agreement with recent observations of others 
(20). 
I t  is tempting to speculate about the underlying 
mechanisms explaining this phenomenon, particu- 
larly the question of why a chronic reduction 
of Q would cause a readjustment of TPR in most 
patients. Resetting of baroreceptors has been sug- 
gested ( IS )  and our data suggest a change of 
baroreceptors to a more sensitive setting. For a 
given increase of systolic BP a comparatively 
greater reduction of HR occurred after treatment. 
However, it should be stressed that we could not 
demonstrate a significant change of baroreceptor 
sensitivity, possibly due to the small number of 
patients available for this comparison. Further- 
more it should be pointed out that a comparison 
to baroreceptor sensitivity was not made after 
acute p-adrenergic blockade. However, studies of 
the baroreceptor sensitivity, using the same tech- 
nique as in the present study, although revealing 
some gain of reflex sensitivity after i.v. pro- 
pranolol, showed that atropinization completely 
abolished the HR response to BP elevation (19). 
This would indicate that vagal effects are mainly 
responsible for the barorecptor-mediated reduc- 
tion of HR and consequently it would be justified 
to compare the sensitivity in the untreated state to 
that after prolonged oral P-adrenergic block- 
ade. Preliminary unpublished data of our own 
reveal that acute i.v. administration of propranolol, 
0.22 mg/kg, does not significantly alter the BP/ 
Our tilt results do not support the opinion by 
Oparil et al. (13) that renin plays an important 
role in the hemodynamic adjustments associated 
with postural changes. The vascular response to 
tilt after prolonged p-adrenergic blockade was not 
impaired in spite of marked reduction of PRA. It 
would therefore seem that renin/angiotensin is not 
R-R slope. 
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Finally, the response to isoproterenol infusion 
failed t o  single out non-responders. However, we 
d o  not wish to  draw any conclusions from this, 
as individual dose-response curves before and 
after propranolol were not made. 
directly responsible for the hemodynamic altera- 
tions during the acute change of posture. 
The  hypothesis that the hypotensive effect of 
propranolol is secondary to  its local anesthetic 
effect and that in fact the reduction of BP would 
follow from anesthesia of vasoconstrictor fibers 
(4) is most interesting. However, it is hard t o  ex- 
plain the different response t o  acute and chronic 
therapy using this explanation. Furthermore 
studies in man, using the dextroisomer of pro- 
pranolol, which has no p-adrenergic blocking ef- 
fect but retains the local anesthetic effect, have 
shown no hypotensive effect (22). Tarazi and 
Dustan (20) were the first t o  publish results indi- 
cating that reduction of BP during propranolol 
treatment follows from a long-term adaptation of 
peripheral resistance. Obviously our results are in 
full agreement with their statement, even if a t  
present we are not able t o  explain the mechanism 
underlying this adjustment. 
The marked reductions of stimulated PRA, and 
therefore logically also of angiotensin 11, could 
theoretically reduce peripheral vascular resistance. 
However, the renin/angiotensin mechanism is not 
considered t o  be of etiological importance in mild 
essential hypertension, and PRA is usually normal 
or even low in this condition (3, 10). Our results 
are in agreement with such a view, as no signifi- 
cant correlation was seen between the change of 
PRA and the changes of MAP, Qi and, most im- 
portantly, TPRi. Furthermore, the reduction of 
PRA was equally pronounced in the three patients 
who showed n o  decrease of MAP. This indicates 
that reduction of PRA is not the major determinant 
of the antihypertensive mechanism of propranolol 
in mild essential hypertension. The  lack of correla- 
tion between the change of PRA and the change of 
TPRi indicates that the readjustment of peripheral 
vascular resistance that takes place during pro- 
longed treatment with propranolol is independent 
of the change of PRA. 
Plasma propranolol concentration was not found 
to  be correlated t o  either the hemodynamic 
changes or the effects of i.v. infusion of iso- 
proterenol, which is in agreement with recent ob- 
servations by others (24). This could indicate that 
tissue binding of propranolol is of greater im- 
portance than the plasma concentration. Other 
possibilities are that active metabolites, e.g. 4- 
hydroxypropranolol, contribute significantly t o  the 
degree of 8-adrenergic blockade. 
3-742981 
CONCLUSIONS 
I .  Acute P-adrenergic blockade does not cause 
reduction of BP in patients with essential hyper- 
tension. The reduction of Q in this situation is 
compensated by a corresponding increase of TPR, 
thereby maintaining BP unaltered. 
2. After four weeks of p-adrenergic blockade 
the Qi is still reduced but, due t o  a n  adjustment of 
TPR, the BP is significantly reduced in most pa- 
tients. 
3. The alterations of TPR and B P  are not di- 
rectly dependent on the marked reductions of 
stimulated PRA. 
4. An increase of the BP/R-R slope, although 
not statistically significant, indicated that baro- 
receptors may have been reset towards a greater 
sensitivity, thereby suggesting the mechanism 
whereby peripheral resistance is adjusted. 
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